Edward Zecchini Sells 1,400 Shares of CryoPort (NASDAQ:CYRX) Stock

CryoPort, Inc. (NASDAQ:CYRX) insider Edward Zecchini sold 1,400 shares of the business’s stock in a transaction dated Wednesday, June 10th. The stock was sold at an average price of $15.23, for a total transaction of $21,322.00. Following the sale, the insider directly owned 109,719 shares in the company, valued at $1,671,020.37. This trade represents a 1.26% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

CryoPort Price Performance

Shares of NASDAQ:CYRX opened at $14.62 on Friday. The company’s 50-day moving average price is $12.42 and its two-hundred day moving average price is $10.33. CryoPort, Inc. has a one year low of $6.16 and a one year high of $16.73. The stock has a market capitalization of $736.88 million, a PE ratio of 10.83 and a beta of 1.90.

CryoPort (NASDAQ:CYRX) last issued its quarterly earnings results on Monday, May 4th. The company reported ($0.23) EPS for the quarter, missing the consensus estimate of ($0.20) by ($0.03). CryoPort had a negative return on equity of 7.92% and a net margin of 41.57%.The business had revenue of $47.80 million for the quarter, compared to the consensus estimate of $44.86 million. On average, analysts anticipate that CryoPort, Inc. will post -0.85 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of CYRX. UBS Group AG grew its stake in CryoPort by 6.8% in the 4th quarter. UBS Group AG now owns 1,421,884 shares of the company’s stock valued at $13,650,000 after buying an additional 90,363 shares during the last quarter. Mak Capital One LLC acquired a new position in CryoPort in the 3rd quarter valued at about $7,756,000. First Eagle Investment Management LLC acquired a new position in CryoPort in the 4th quarter valued at about $2,996,000. Legato Capital Management LLC acquired a new position in CryoPort in the 4th quarter valued at about $443,000. Finally, Segall Bryant & Hamill LLC acquired a new position in CryoPort in the 3rd quarter valued at about $652,000. 92.90% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several equities research analysts have commented on the stock. Needham & Company LLC boosted their price target on shares of CryoPort from $13.00 to $15.00 and gave the stock a “buy” rating in a research report on Tuesday, May 5th. Weiss Ratings upgraded shares of CryoPort from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Wednesday, May 6th. BTIG Research boosted their price objective on shares of CryoPort from $15.00 to $17.00 and gave the stock a “buy” rating in a research note on Tuesday, May 5th. Jefferies Financial Group set a $13.50 price objective on shares of CryoPort in a research note on Monday, June 8th. Finally, Wall Street Zen upgraded shares of CryoPort from a “sell” rating to a “hold” rating in a research note on Monday, May 11th. Eight equities research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. Based on data from MarketBeat, CryoPort currently has an average rating of “Moderate Buy” and a consensus target price of $15.11.

CryoPort Company Profile

CryoPort, Inc (NASDAQ: CYRX) is a global provider of temperature-controlled logistics solutions for the life sciences industry. The company specializes in cryogenic shipping for critical biological materials, supporting the development, clinical testing and commercialization of cell and gene therapies, biologics, vaccines and reproductive medicine. By offering end-to-end supply chain management, CryoPort helps ensure the integrity and viability of temperature-sensitive products from point of origin to destination.

CryoPort’s product portfolio includes proprietary cryogenic dry shippers, advanced active and passive thermal packaging, and real-time data monitoring platforms.